TLR4 and neoplasm: Recently, Carlos W et al. used mouse tumour model to demonstrate that paclitaxel inhibited tumour progression by reprogramming the phenotypes of TAMs from a M2 pro‐tumour subtype to a M1 antitumour subtype in a TLR4‐dependent manner.48